A Single-site, Randomized, Double-blind, Placebo-controlled, Repeated-dose Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in 2 Different Dosages (2 mg / 24 Hours [10 cm2], 4 mg / 24 Hours [20 cm2]) in Healthy Korean Subjects
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors UCB
- 23 Oct 2013 New trial record